{"name": "AEterna Zentaris",
 "permalink": "aeterna-zentaris",
 "crunchbase_url": "http://www.crunchbase.com/company/aeterna-zentaris",
 "homepage_url": "http://www.aezsinc.com/",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": null,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "",
 "phone_number": "(418) 652-8525",
 "description": "",
 "created_at": "Thu Mar 10 06:16:01 UTC 2011",
 "updated_at": "Sat Apr 20 13:14:30 UTC 2013",
 "overview": "\u003Cp\u003EAEterna Zentaris Inc. is a drug development company specialized in oncology and endocrine therapy. The Company\u00e2\u20ac\u2122s product pipeline encompasses compounds at all stages of development, from drug discovery through marketed products. The priorities in oncology are its Phase III program with perifosine in multiple myeloma and its Phase II program in multiple cancers, including metastatic colon cancer, as well as Phase II program with AEZS-108 in advanced endometrial and advanced ovarian cancer combined with potential developments in other cancer indications. In endocrinology, the Company\u00e2\u20ac\u2122s program is the reactivation of a Phase III trial with AEZS-130 (SolorelTM) as a growth hormone (GH) stimulation test for the diagnosis of GH deficiency in adults (AGHD). \u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[147,
       30],
      "assets/images/resized/0012/5750/125750v1-max-150x150.png"],
     [[147,
       30],
      "assets/images/resized/0012/5750/125750v1-max-250x250.png"],
     [[147,
       30],
      "assets/images/resized/0012/5750/125750v1-max-450x450.png"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [{"is_past": false,
    "title": "President and Chief Executive Officer",
    "person":
     {"first_name": "David",
      "last_name": "A. Dodd",
      "permalink": "david-a-dodd",
      "image": null}},
   {"is_past": true,
    "title": "President and CEO",
    "person":
     {"first_name": "J\u00c3\u00bcrgen",
      "last_name": "Engel",
      "permalink": "jrgen-engel",
      "image": null}}],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$0",
 "funding_rounds":
  [],
 "investments":
  [],
 "acquisition": null,
 "acquisitions":
  [],
 "offices":
  [{"description": "",
    "address1": "1405 du Parc-Technologique Blvd.",
    "address2": "",
    "zip_code": "G1P 4P5",
    "city": "Qu\u00c3\u00a9bec",
    "state_code": null,
    "country_code": "CAN",
    "latitude": null,
    "longitude": null}],
 "milestones":
  [{"description": "Aeterna Zentaris snags $69M pact on perifosine",
    "stoned_year": 2011,
    "stoned_month": 3,
    "stoned_day": 9,
    "source_url": "http://www.fiercebiotech.com/story/aeterna-zentaris-snags-69m-pact-perifosine/2011-03-09?utm_medium=rss\u0026utm_source=rss",
    "source_text": "",
    "source_description": "Aeterna Zentaris snags $69M pact on perifosine",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "AEterna Zentaris",
      "permalink": "aeterna-zentaris"}}],
 "ipo":
  {"valuation_amount": null,
   "valuation_currency_code": "USD",
   "pub_year": null,
   "pub_month": null,
   "pub_day": null,
   "stock_symbol": "NASDAQ:AEZS"},
 "video_embeds":
  [],
 "screenshots":
  [{"available_sizes":
     [[[141,
        150],
       "assets/images/resized/0012/5763/125763v1-max-150x150.jpg"],
      [[236,
        250],
       "assets/images/resized/0012/5763/125763v1-max-250x250.jpg"],
      [[425,
        450],
       "assets/images/resized/0012/5763/125763v1-max-450x450.jpg"]],
    "attribution": null}],
 "external_links":
  []}